Agenus Inc
NASDAQ:AGEN

Watchlist Manager
Agenus Inc Logo
Agenus Inc
NASDAQ:AGEN
Watchlist
Price: 3.15 USD -1.25%
Market Cap: $107.1m

Operating Margin

-58.9%
Current
Improving
by 67.2%
vs 3-y average of -126.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-58.9%
=
Operating Income
$-62.9m
/
Revenue
$106.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-58.9%
=
Operating Income
$-62.9m
/
Revenue
$106.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Agenus Inc
NASDAQ:AGEN
104.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 82% of companies in the United States of America
Percentile
18th
Based on 14 112 companies
18th percentile
-58.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Agenus Inc
Glance View

Market Cap
107.1m USD
Industry
Biotechnology

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2000-02-04. The company has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Its clinical-stage asset portfolio also includes Botensilimab (AGEN1181), AGEN2373, AGEN1423, AGEN1777, MK-4830, INCAGN2390, INCAGN2385 and AGENT 797. The company is developing personalized vaccines, namely Prophage and AutoSynVax, and off-the-shelf vaccines PhosphoSynVax, which contains heat shock proteins to deliver neoantigens to the right immune cells to activate an anti-cancer immune response.

AGEN Intrinsic Value
10.69 USD
Undervaluation 71%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-58.9%
=
Operating Income
$-62.9m
/
Revenue
$106.8m
What is Agenus Inc's current Operating Margin?

The current Operating Margin for Agenus Inc is -58.9%, which is above its 3-year median of -126.1%.

How has Operating Margin changed over time?

Over the last 3 years, Agenus Inc’s Operating Margin has increased from -198.8% to -58.9%. During this period, it reached a low of -213.4% on Sep 30, 2023 and a high of -58.9% on Sep 30, 2025.

Back to Top